Brain fog is one of those complaints that is hard to explain and hard to ignore, and a physician such as Dr. Bissoon will tell you that it deserves a real workup before it deserves a procedure. Words go missing mid sentence. A task that used to take an hour takes three. You walk into a room and the reason is gone. When a person has lived with that for months, and standard tests have come back normal, an idea starts to look attractive: if something in the blood is clouding the mind, perhaps removing it would help. That idea is the reason many people now search for plasma exchange and brain fog in the same sentence.
The idea is not absurd. There is a respectable line of research behind it, and one large clinical trial in Alzheimer's disease that is cited more often than it is read. But the distance between that trial and a middle aged professional with foggy afternoons is large, and anyone considering the treatment for cognitive reasons deserves to see the distance clearly.
This article goes through what brain fog is, what the plasma hypothesis proposes, what the AMBAR trial did and did not examine, what plasma exchange can and cannot be said to do for thinking, and what a careful physician would want to rule out first. It is written for patients in New York, and it makes no promises.
Part of the appeal is metaphor. Blood circulates everywhere, including to the brain, so it is natural to imagine that a dirty or sluggish circulation might cloud thinking, and that cleaning it would clear it. The metaphor is intuitive, and it is also how marketing works: a simple story about toxins and cleansing is easier to remember than a list of causes.
Part of the appeal is also real science. Experiments in animals have shown that the composition of blood can influence the aging of tissues, including the brain, and that exchanging plasma between young and old animals changes certain markers. Those experiments set off a wave of interest in whether altering human plasma could have effects that matter.
The gap between a compelling story and an established treatment is where most of the hard thinking belongs. A person who understands that gap is better placed to decide whether to explore plasma exchange, and to hold a clinic to an honest standard if they do.
Brain fog is not a diagnosis. It is a description that people use for a cluster of experiences: slowed thinking, difficulty concentrating, trouble finding words, short term forgetfulness and mental fatigue. It is common, and it has many causes, most of them treatable and most of them unrelated to anything circulating in plasma.
Sleep problems top the list, including untreated sleep apnea and chronically short or fragmented sleep. Thyroid disorders and vitamin B12 deficiency produce it. So do anemia, blood sugar swings and certain medications. Depression and anxiety present with it. Perimenopause and menopause bring it for many women, and low testosterone can contribute in men. Recovery from infections, including viral illnesses, can leave it behind for weeks or months. Alcohol, stress and overwork play their part.
A related thread is the digestive system. Inflammation that starts in the gut can influence mood and mental clarity, and many patients with persistent fog also report bloating, food reactions or irregular digestion. The connection between gut health and the way a person feels mentally is real enough to warrant a question about digestion during any evaluation.
Recovery from infection deserves its own mention. After influenza, COVID-19 or other viral illness, many people describe weeks or months of mental slowness, along with fatigue and poor exercise tolerance. For most, this fades gradually. When it does not, the evaluation should look at sleep, autonomic function, thyroid and nutritional status before attributing it to a single cause. Small reports have explored blood cleansing procedures for post-viral symptoms, but the evidence is preliminary and should be read with the same caution as everything else here.
Because the causes are so varied, treating brain fog as a single problem with a single solution is a mistake. The first job is to find out which of these, if any, applies. This is why a thorough evaluation, not a procedure, is the right first step, and why the hormonal signals that appear alongside cognitive complaints deserve attention before anyone considers a blood treatment.
The hypothesis behind plasma based approaches to the brain goes roughly like this. The blood contains proteins and other molecules, some of which are linked to inflammation or to the buildup of abnormal proteins, including amyloid beta, which accumulates in the brains of people with Alzheimer's disease. Some amyloid beta also circulates in plasma, bound largely to the protein albumin. If you remove plasma and replace it with a clean albumin solution, the argument goes, you might lower levels in the blood, which could in turn draw amyloid out of the brain, a concept sometimes called a peripheral sink. Separately, replacing old plasma with something else might alter signaling molecules associated with aging.
Notice how many steps that is. Each of them is a hypothesis, and each needs to be tested. The only way to know whether the chain holds is to run careful trials in people and measure what happens to their thinking, not just to their blood. That is what the AMBAR trial set out to do for Alzheimer's disease.
Much of the public excitement traces to experiments in which scientists joined the circulations of young and old animals, or injected plasma from young animals into old ones, and observed changes in muscle, liver and brain tissue. Those results were genuinely interesting, and they raised the possibility that factors in blood help set the pace of aging.
What happened next is a familiar pattern. Headlines turned an animal finding into a promise for people, companies formed, and clinics in the fast growing field of longevity medicine began offering treatments before the human data existed. Later work has been more sobering, with debate about which factors matter, whether the effects come from adding something young or diluting something old, and how much transfers across species. The most defensible reading is that blood composition plausibly influences aging, that how to use that fact safely in people is still being worked out, and that the broader argument for prevention rests mostly on measures that start long before symptoms.
AMBAR, which stands for Alzheimer's Management by Albumin Replacement, was a randomized, placebo controlled clinical trial conducted in Spain and the United States. Its participants had mild to moderate Alzheimer's disease. Several hundred people were randomized to one of several treatment arms or to a sham procedure, in which people went through a process designed to look like plasma exchange without actually performing it.
The treatment arms received plasma exchange with albumin replacement, an initial intensive phase of weekly sessions followed by a longer maintenance phase of less frequent sessions over about a year. The trial measured cognitive function with a standard scale used in Alzheimer's research and functional ability, meaning the capacity to carry out everyday tasks, with another. It also examined biomarkers in blood and spinal fluid.
Several features of this design are worth noticing, because they are exactly what a good trial should include: random assignment, a sham comparison, standard outcome measures and a long enough follow up to see whether anything changed. It is one reason AMBAR is taken seriously, and one reason it is more informative than the anecdotes that circulate on social media.
The investigators reported that people who received the treatment declined less on the cognitive and functional measures than those who received the sham procedure, and that the benefit appeared larger in people with moderate disease than in those with mild disease. They also reported changes in amyloid beta levels in blood and spinal fluid in the treated groups.
Those are the headline findings, and they are the reason the trial is cited so often. They are also a good example of a result that is easy to summarize and hard to interpret. A single trial of this kind, even a well designed one, does not establish a treatment. Results that look promising need to be reproduced by other investigators, in other populations, with other protocols. Subgroup differences, such as stronger effects in moderate disease, are especially vulnerable to chance, and they raise as many questions as they answer.
Reporting this fairly means saying that the trial gave a reason to keep studying plasma exchange in Alzheimer's disease, not that it settled the matter. Plasma exchange is not an approved treatment for Alzheimer's disease in the United States, and a physician who describes it as one is overstating the evidence.
This is the section most summaries leave out, and it matters more than the previous two.
AMBAR did not study people with brain fog. Its participants had a diagnosis of Alzheimer's disease, with measurable cognitive impairment, and the question was whether the course of that illness could be altered. It did not enroll healthy middle aged adults, and it did not measure whether people with ordinary cognitive complaints think more clearly after treatment.
AMBAR also tested a specific protocol: plasma exchange with albumin replacement, on a defined schedule, under the control of the investigators. A different protocol, such as exchange with a different replacement fluid, a different frequency or the addition of other agents, is a different treatment. Results from one do not automatically transfer to the other.
And AMBAR was not a long term study of safety and benefit across years. It followed participants for a limited period. Whether any effects persist, and what repeated treatment over many years does, remain open questions.
None of this diminishes the trial. It simply means that citing it as evidence that plasma exchange clears brain fog is stretching the result well beyond what it measured.
Think about what extrapolation requires. A treatment is tested in people with a specific disease, using a specific protocol, and the result is cautiously positive on specific measures. To apply that result to a different person, you need to assume that their condition shares the relevant mechanism, that the protocol being offered matches the one tested, and that the outcome you care about is one the trial measured.
For a patient with brain fog and no diagnosed neurodegenerative disease, none of those assumptions can be verified. Brain fog might stem from sleep, thyroid, hormones, medications or mood, none of which involve amyloid in plasma. The protocol offered may differ from the trial's. And the outcome the patient cares about, thinking more clearly at work, is not what the trial measured.
This is not an argument against exploring plasma exchange. It is an argument for describing it accurately, which means as an area of active investigation with a plausible rationale, not as a proven remedy for foggy thinking. A sober reading of the trial evidence takes the same cautious line, and it is the right model for how to read the literature.
Another study frequently cited alongside AMBAR is a small 2025 trial in adults over fifty that examined plasma exchange, with and without added immunoglobulin, and measured changes in several estimates of biological age derived from patterns in DNA and other markers. The authors reported differences in those estimates after treatment, and the finding drew wide attention.
It deserves a careful reading too, because this is exactly the corner of the field where enthusiasm tends to outrun the data. Biological age estimates, often called clocks, are statistical models. They correlate with health outcomes across populations, but a change in a clock after an intervention does not establish that a person is healthier, lives longer or thinks better. Whether moving a clock reflects a real change in the underlying biology is a subject of active debate.
The study also enrolled a small number of participants and did not set out to measure cognition. It is a useful early signal. It is not evidence that plasma exchange improves memory, and a clinic that presents it that way is making a leap the data do not support.
Plasma is not a bag of toxins. It contains albumin, antibodies, clotting factors, hormones, nutrients and thousands of other proteins the body needs. When plasma is removed and replaced, all of these are removed along with whatever else is present, and the replacement fluid, usually albumin with saline, restores volume and protein but not every component.
For most healthy people, the body replenishes what is lost over time. Still, antibodies and clotting factors are lower after a session, which is one reason the treatment is not suited to everyone and why spacing and screening matter. Some programs add immunoglobulin replacement to address the antibody loss, which brings its own considerations.
Understanding this helps with a common marketing claim, that plasma exchange removes toxins. The process is nonselective: it removes plasma and its constituents, good and bad. Whether the net effect is beneficial depends on what is being removed, what is replaced and who the patient is. Honest discussion of selectivity is a sign of a thoughtful clinic.
Plasma exchange is a medical procedure, and it carries the risks of one. It requires venous access, typically through needles in both arms or a catheter, with the risks of bruising, infection and, rarely, vein or nerve injury. The anticoagulant used to keep blood from clotting in the machine can lower calcium temporarily, which can cause tingling around the mouth or fingers, cramps and, if severe, more serious symptoms, so staff monitor for it and supplement calcium as needed.
Changes in blood volume and pressure can cause light headedness or low blood pressure. Allergic reactions to replacement fluids are uncommon but possible. Loss of antibodies and clotting factors raises theoretical concerns about infection and bleeding in the days after treatment. Sessions take hours, and patients usually need to arrange the rest of the day around them. Fluid and food beforehand, comfortable clothing and someone to accompany you home if you feel light headed are sensible precautions, and the staff should explain what to expect before you begin, not while the needles are going in.
People with certain conditions, including bleeding disorders, active infections, some heart and kidney problems and allergies to the replacement solutions, are generally not candidates. The screening that decides candidacy is more detailed than this overview, and a physician should go through your history before any session is scheduled.
A careful evaluation for cognitive complaints begins with listening, which is where a physician led approach starts. When did it start? Was there an illness, a life change, a new medication, a bad stretch of sleep? Is it constant or does it vary with the time of day, meals or the menstrual cycle? Does it affect memory, attention, word finding or all three? Do others notice it?
Next comes the medical review: medications, alcohol, sleep patterns, snoring, mood, stress, and a family history of dementia. Then laboratory testing guided by the story, which commonly includes thyroid function, vitamin B12, blood count, glucose and metabolic markers, inflammatory markers, and hormones where relevant. For many women in their forties and fifties, the hormonal transition is central, and the research linking hormones to long term brain health, discussed in the context of hormone therapy, is part of the picture.
If the history suggests it, a physician may recommend a sleep study, formal cognitive testing or a neurological referral. The point is not to delay treatment but to make sure the right problem is being treated. A foggy mind that turns out to be sleep apnea does not need plasma exchange, and the correct diagnosis is worth more than any procedure.
If there is one question that explains more brain fog than any other, it is how a person sleeps. Not just how long, but whether the sleep is continuous and restorative. Loud snoring, gasping, morning headaches, a dry mouth on waking and daytime sleepiness suggest sleep apnea, which is common, underdiagnosed and treatable, and which impairs attention and memory as reliably as anything else on this list.
Even without apnea, short or irregular sleep produces slowed thinking, and the effect accumulates. Before a person invests in an advanced treatment, a few weeks of consistent sleep timing, a cool dark room and a limit on late caffeine and alcohol often change how the afternoons feel. It is an unglamorous experiment, and it is the cheapest one available.
Suppose, after a thorough evaluation, a patient and physician decide that plasma exchange is worth considering for reasons that include cognitive complaints. A sensible approach resembles good clinical practice anywhere. Establish a baseline before treatment, using something more objective than a feeling: validated cognitive screening tests, sleep and mood measures, and laboratory markers. Define in advance what change would count as meaningful. Choose a defined course of treatment, then repeat the measurements afterward.
Pre and post treatment laboratory work is part of this, and the way the practice documents changes is described in its explanation of lab results. Cognitive testing adds a layer that blood tests cannot provide.
It also matters to be honest about the limits of self report. A person who has invested time and money, and who expects to feel clearer, is likely to feel clearer for reasons unrelated to the treatment. Objective measures protect against that, and a clinic that measures is more credible than one that relies on testimonials.
Plasma exchange is not new. Hospitals have used it for decades to treat particular autoimmune, neurological and blood disorders, where indications, protocols and monitoring are set out in guidelines and the benefit is established. A patient with one of those conditions receives it as medicine in the full sense.
The longevity application is a different audience and a different level of evidence. Here the treatment is offered to people who are not acutely ill, for goals like healthy aging, cognitive clarity and removal of accumulated substances. That context is where careful language matters most. A practice offering plasma exchange in New York for these purposes should be able to explain which of its statements rest on hospital experience, which on early studies and which on reasoning that has not yet been tested.
Plasma exchange is established for certain medical conditions in hospitals, such as particular autoimmune and neurological disorders, where its role is defined by guidelines. Its use for longevity and cognitive aims is newer, less established and more experimental. A physician who offers it in that setting should say so.
The patients for whom it is most reasonably discussed are generally adults, often over fifty, who are proactive about health, have completed a thorough evaluation, have no contraindications and understand that the evidence is early. The patients for whom it is least appropriate are those hoping for a quick fix for a symptom whose cause has not been identified.
How plasma exchange compares with other approaches is a separate question, addressed in the discussion of other treatments. For cognitive aims specifically, it sits alongside options with a longer track record, which are worth naming.
Several measures have more robust support for cognitive health than any blood procedure. Regular aerobic exercise is among the most consistently supported. Treating high blood pressure in midlife is associated with lower dementia risk. Addressing hearing loss, getting enough sleep, treating sleep apnea, maintaining social and intellectual engagement, limiting alcohol and managing blood sugar all appear in the literature on brain health.
None of these is exciting, and all of them can be done alongside other care. They are also the reason the broader case for prevention begins decades before symptoms. A person who does these things reliably has done more for their brain than most procedures could offer, and would be a better candidate for any additional step.
The philosophy here is the one behind shifting from sick care to health care: look for causes early, change what can be changed, and add advanced therapies on top of a sound foundation, not instead of one.
One more thing worth separating is the vocabulary of cleansing. Plasma exchange is sometimes described as a way to clear environmental contaminants, including microplastics and certain chemicals, from the blood. That is a different claim from a cognitive one, with its own evidence and its own limits, and the microplastics question in particular is worth reading about on its own terms. Claims about microplastics and claims about cognition rise or fall independently.
The two claims are often blended in conversation, and blending them makes both harder to evaluate. A treatment might lower a circulating chemical without changing how clearly a person thinks, and a change in thinking might occur for reasons unrelated to any chemical. Keeping the claims separate lets each be judged on its own evidence. That is a standard worth applying to every claim you meet, including the ones in this article.
If brain fog is what brings you to this subject, the most useful first step is not to book a procedure but to have the evaluation, and the office will take your questions if you contact it. Expect questions before answers, because the history and the laboratory work are what make any later recommendation meaningful, and bring a timeline of when symptoms began, a list of medications and supplements, notes on sleep, and any recent laboratory results. Be ready to describe a typical day and the moments when the fog is worst.
For some patients the answer will be a hormone adjustment or a sleep intervention. For others, plasma exchange may be a reasonable part of a longer strategy. In every case the aim is to understand your situation before recommending anything, and that order of operations is a good sign in any clinic. A plan built that way can always add an advanced therapy later, whereas one that begins with the therapy rarely goes back to ask the questions it skipped.
There is no evidence that plasma exchange cures brain fog. Brain fog has many causes, including sleep problems, thyroid disorders, hormones and medications, and the cause should be identified first.
AMBAR was a randomized, placebo controlled trial of plasma exchange with albumin replacement in people with mild to moderate Alzheimer's disease. The investigators reported slower decline in treated groups, and the findings called for further study.
No. Plasma exchange is not approved for Alzheimer's disease in the United States. The AMBAR results are promising for research purposes but do not establish it as a standard treatment.
Not directly. The trial enrolled people with diagnosed Alzheimer's disease and tested a specific protocol, so its results cannot be assumed to apply to healthy adults or to ordinary cognitive complaints.
Risks include bruising, infection and vein irritation at access sites, low calcium from the anticoagulant, low blood pressure, allergic reactions to replacement fluids and temporary loss of antibodies and clotting factors. Screening reduces but does not remove these risks.
It removes plasma and everything in it, including proteins the body needs, and replaces it with fluid. It is not selective, so describing it as removing only toxins overstates what the process does.
People with bleeding disorders, active infections, allergies to replacement fluids, or certain heart and kidney conditions are generally not candidates. A physician reviews your history before a session is scheduled.
Sleep, thyroid function, vitamin B12, blood count, blood sugar, hormones, medications, mood and alcohol use are the usual starting points. A physician may add a sleep study or cognitive testing depending on the history.
By measuring before and after, using objective cognitive tests, sleep and mood measures and laboratory markers, along with how you feel. Feeling better alone can reflect expectation, so objective measures matter.
No. Biological age estimates are statistical models, and a change in one does not show that thinking has improved. Small studies using them are early signals and not evidence of cognitive benefit.
Regular aerobic exercise, good sleep, treating sleep apnea and high blood pressure, addressing hearing loss, limiting alcohol and staying socially and mentally active have the strongest support.
Generally no. A physician will usually evaluate and treat common causes first and consider plasma exchange later, if at all, once the evaluation is complete and you understand the limits of the evidence.
This page was written and medically reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan.
This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.
Published
